Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesScancell Hldgs Plc

Scancell Hldgs Plc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
89.0 GBX -1.00 ( 1.11%)
Last update at 2026-10-27T17:15:00Z
VOLUME
660713
Market Cap
127.13M

Momentum Score

…

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
88.00
Low
92.00
High
52 Week Price Range
7.86
Low
14.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Scancell Holdings is a UK clinical-stage biotechnology company developing cancer immunotherapies with proprietary platforms to generate tumor-specific T‑cell responses. Long-term growth may be supported by positive trial readouts, collaborations or licensing and development of combination regimens. Investors may find the company attractive because its differentiated approaches appear positioned to enable partnering and program value creation if data are supportive.

Key risks include high likelihood of clinical or regulatory setbacks, limited revenue and ongoing funding needs that could dilute shareholders, and intense competition from larger immuno-oncology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
90.00
Dividend Yield
-
Revenue TTM
4.71M
Revenue Per Share
0.01
Gross Profit TTM
4.47M
Debt / Equity
-4.24
ROE
-269.84%
Net Debt
-0.63M
ROCE
366.00%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Income before tax -15.30M -9.12M -14.30M -3.77M -16.80M
Net income -12.27M -5.86M -11.94M -2.06M -15.48M
Selling general administrative 4.79M 5.40M 5.02M 4.79M 3.35M
Gross profit 3.59M -0.97M 4.75M - -
Reconciled depreciation 0.88M 0.97M 0.90M 0.74M 0.25M
Ebit -13.59M -8.03M -11.64M -13.30M -8.83M
Ebitda -12.71M -7.06M -10.73M -7.31M -14.90M
Depreciation and amortization 0.88M 0.97M 0.90M 5.99M -6.07M
Operating income -15.00M -18.27M -11.92M -13.30M -8.83M
Other operating expenses 19.71M 18.27M 17.19M 13.30M 8.83M
Interest expense 1.72M 1.09M 1.22M 2.88M 1.65M
Tax provision -3.03M -3.26M -2.37M -1.70M -1.33M
Interest income 0.34M 0.35M 0.28M 0.00M 0.00M
Net interest income -1.38M -0.73M -0.93M 2.37M -7.97M
Income tax expense -3.03M -3.26M -2.37M -1.70M -1.33M
Total revenue 4.71M 0.00M 5.27M 0.00M 0.00M
Total operating expenses 18.59M 17.30M 16.67M 13.30M 8.83M
Cost of revenue 1.12M 0.97M 0.53M - 6.41M
Total other income expense net -0.30M 9.15M -2.38M 9.53M -7.97M
Net income from continuing ops -12.27M -5.86M -11.94M -2.06M -15.48M
Net income applicable to common shares - - - -2.06M -15.48M
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Total assets 23.09M 23.58M 30.27M 49.06M 8.82M
Intangible assets 1.62M - - - -
Other current assets 0.11M 1.20M - 3.64M 3.56M
Total liab 26.93M 27.08M 36.50M 29.57M 1.17M
Total stockholder equity -3.83M -3.50M -6.23M 19.48M 7.65M
Other current liab 10.66M 2.72M - 0.34M 1.20M
Common stock 1.04M 0.93M 0.82M 0.81M 0.47M
Capital stock 1.04M 0.93M 0.82M 0.81M 0.81M
Retained earnings -91.42M -84.19M -74.36M -47.05M -31.58M
Other liab - - - 10.10M 12.03M
Good will - - 3.42M 3.42M 3.42M
Cash 16.89M 14.82M 19.92M 41.11M 3.58M
Total current liabilities 26.80M 6.39M 3.28M 2.29M 1.17M
Net debt -0.63M 5.05M -0.39M -25.66M -3.45M
Short term debt 16.14M 2.03M 0.31M 0.21M 0.13M
Short long term debt 15.75M 1.61M - - -
Short long term debt total 16.27M 19.87M 19.53M 15.46M 0.13M
Other stockholder equity 82.40M 79.75M 67.30M 65.72M 38.76M
Property plant equipment - - - 2.74M 0.97M
Total current assets 20.62M 21.87M 24.61M 44.67M 5.21M
Net tangible assets - - - 14.70M 16.07M
Net receivables 3.73M 5.85M 0.54M 3.19M 3.56M
Long term debt 0.00M 17.37M 18.48M 7.01M 15.18M
Inventory - 0.53M - - -
Accounts payable 0.61M 1.46M 2.97M 2.09M 1.04M
Accumulated other comprehensive income 4.14M 2.78M - - -
Non current assets total 2.47M 1.71M 5.66M 4.39M 3.61M
Capital lease obligations 0.51M 0.89M 1.05M 1.17M 0.27M
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Investments -1.20M 0.18M 0.08M -1.26M -0.74M
Change to liabilities - - - 0.05M 1.05M
Total cashflows from investing activities -1.54M 0.18M - -1.26M -0.74M
Net borrowings -0.45M 0.00M - -0.39M 23.35M
Total cash from financing activities 9.73M 10.39M -0.75M 46.08M 3.80M
Net income -12.27M -9.12M -14.30M -16.80M -6.77M
Change in cash 2.08M -5.10M -8.80M 37.53M -0.98M
Begin period cash flow 14.82M 19.92M 28.73M 3.58M 4.56M
End period cash flow 16.89M 14.82M 19.92M 41.11M 3.58M
Total cash from operating activities -6.11M -15.66M -8.14M -7.80M -4.77M
Issuance of capital stock 11.28M 11.99M 0.17M 0.00M 24.14M
Depreciation 0.88M 0.97M 0.90M 0.25M 0.04M
Other cashflows from investing activities - 0.35M - 0.00M 0.00M
Change to account receivables 0.75M -0.84M - 0.32M -0.60M
Sale purchase of stock - - - - 24.14M
Other cashflows from financing activities -0.40M -1.60M -0.91M 21.94M -0.08M
Change to netincome - - - -9.24M 6.98M
Capital expenditures 0.01M 0.18M 0.20M 0.74M 0.03M
Change in working capital 0.73M -0.71M 0.94M 0.45M 0.14M
Stock based compensation 1.36M 0.66M 0.73M 0.33M -0.01M
Other non cash items 4.55M -7.46M 2.38M 7.97M -0.01M
Free cash flow -6.12M -15.84M -8.34M -8.55M -4.80M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SCLP
Scancell Hldgs Plc		 -1.00
1.11%		 89.00 - 3.54 26.99 8.89 26.40 -10.48
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51 -12.04

Profile*

Scancell Hldgs Plc

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Bellhouse Building, Oxford, United Kingdom, OX4 4GD

44 18 6558 2066

https://www.scancell.co.uk

60

Name Title Year Born
Prof. Lindy Gillian Durrant Ph.D. Founder, CEO, Chief Scientific Officer & Director NA
Dr. Sally Elizabeth Adams Chief Devel. Officer & Director 1961
Mr. Keith Green Director of Fin. & Admin. and Company Sec. NA
Dr. Samantha Paston Ph.D. Head of Translational Research NA
Dr. Adrian Parry Ph.D. Head of Manufacturing NA
Ms. Akua Asare Head of Quality NA
Mr. Fayaz Master Head of Clinical Operations NA
Dr. Phillip John L'Huillier MBA, Ph.D. CEO & Director 1962
Prof. Lindy Gillian Durrant Ph.D. Chief Scientific Officer, Director & Founder 1957
Mr. Sathijeevan Nirmalananthan CFO, Company Secretary & Director 1986

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…